Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | NAAA | Q02083 | 1/20 | 0.36 |
| ▸ | EED | O75530 | 1/20 | 0.35 |
| ▸ | ACP1 | P24666 | 3/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | NPY1R | P25929 | 5/20 | 0.33 |
| ▸ | CPN1 | P15169 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13282815 | 0.88 | HRH3 (0.47) | HRH3TLR7CYP1A2HRH4KMT2A | |
| SCHEMBL892690 | 0.83 | CYP1A2 (0.56) | HRH3TLR7CYP1A2HRH4KMT2A | |
| SCHEMBL5234543 | 0.83 | HRH3 (0.42) | HRH3HRH4KMT2ANAAAACP1 | |
| SCHEMBL5234321 | 0.82 | HRH3 (0.44) | HRH3TLR7HRH4KMT2ANAAA | |
| SCHEMBL5237679 | 0.82 | SIGMAR1 (0.45) | HRH3TLR7HRH4KMT2ANAAA | |
| SCHEMBL5233945 | 0.82 | SIGMAR1 (0.41) | HRH3TLR7HRH4KMT2ANAAA | |
| SCHEMBL14368874 | 0.82 | CYP1A2 (0.48) | HRH3TLR7CYP1A2HRH4KMT2A | |
| Hydrochloric Acid SCHEMBL4424141 | 0.82 | CYP1A2 (0.54) | HRH3TLR7CYP1A2HRH4KMT2A | |
| SCHEMBL902268 | 0.82 | CYP1A2 (0.48) | HRH3TLR7CYP1A2HRH4KMT2A | |
| SCHEMBL14368866 | 0.82 | CYP1A2 (0.48) | HRH3TLR7CYP1A2HRH4KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1084710-B1 | ADENOSINE A1 ANTAGONISTS FOR MALE STERILITY | ASTELLAS PHARMA INC (JP) | 2006-10-18 | — | — | EP | disclosed |
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-08-05 | — | — | US | disclosed |
| US-6521656-B1 | Contacting sperm with a pyrazolo(1,5-a)pyridine acrosomal reaction induction promoter then joining with ovum | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-02-18 | — | — | US | disclosed |
| EP-0823254-B1 | NOVEL USE OF PYRAZOLOPYRIDINE COMPOUNDS | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-07-17 | — | — | EP | disclosed |
| EP-1177797-A9 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| EP-1177797-A1 | NOVEL USE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-02-06 | — | — | EP | disclosed |
| EP-0497258-B1 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO (JP) | 2002-01-02 | — | — | EP | disclosed |
| US-6303624-B1 | PREVENTION AND/OR TREATMENT OF HYPERPHOSPHATEMIA OR SECONDARY HYPERPARATHYROIDISM, INCLUSIVE OF ACCESSORY DISORDERS BY ADMINISTERING A PHARMACEUTICAL COMPOSITION WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-10-16 | — | — | US | disclosed |
| US-6232324-B1 | AS HYPERTENSIVE AGENTS FOR DIALYSIS INDUCED HYPOTENSION; ADMINISTERING COMPOUNDS SUCH AS 1-(3-(2-PHENYLPYRAZOLO(1,5-A) PYRIDIN-3-YL)ACRYLOYL)-2-(CARBOXY METHYL)PIPERIDINE | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-15 | — | — | US | disclosed |
| US-6214843-B1 | TREATING AND/OR PREVENTING GASTROINTESTINAL DYSFUNCTION WITH A PYRAZOLOPYRIDINE COMPOUND WHICH COMPRISES AN ADENOSINE ANTAGONIST COMPOUND OR ITS SALT | FUJITSAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-04-10 | — | — | US | disclosed |
| US-5296490-A | Pharmaceutically useful pyrazolopyridines | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-03-22 | — | — | US | disclosed |
| WO-1993025205-A1 | PYRAZOLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF ANEMIA | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-12-23 | — | — | WO | disclosed |
| US-5179103-A | Diuretics, hypotensive agents | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1993-01-12 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5102878-A | Treating psychological, bone, cardiovascular, blood disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5102869-A | Urogenital disorders | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-04-07 | — | — | US | disclosed |
| US-5087629-A | Diuretics, hypotensive agents; cardiotonic agents | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-02-11 | — | — | US | disclosed |
| US-4994453-A | Treating asthma, diabetes, obesity, immunosuppression | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-02-19 | — | — | US | disclosed |
| US-4925849-A | DIURETICS, HYPOTENSIVE AGENTS, CARIOTONIC AGENTS AND ANTIEDEMIC AGENTS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-15 | — | — | US | disclosed |
| EP-0299209-A2 | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-01-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040152659-A1 | Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist | ADORA2A, ADORA1, ADORA2B | HRH3 301/4885TLR7 757/4885CYP1A2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.